US regulatory status: approved. Molecular target: Elongation factor 2.
- Target
- Elongation factor 2
- Mechanism
- Elongation factor 2 inhibitor
pharma · CTXR
Citius Pharmaceuticals
Citius Pharmaceuticals drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CRANFORD, NJ, USA HQ
Public company Type
CTXR · NYSE Ticker
Company details
- Status
- Public
- HQ
- CRANFORD, NJ, USA
- Programs
- 0
- Drugs
- 1
- Patents
- 0
Citius Pharmaceuticals pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Citius Pharmaceuticals drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.